Lemborexant hits Phase III targets
Eisai and Purdue Pharma have announced six-month results from the SUNRISE 2 Phase III clinical study evaluating the efficacy and safety of lemborexant.
Read More
Tag: Lemborexant
Eisai kicks off mid-stage study of sleep drug
Eisai has kicked off a mid-stage study assessing its potential first-in-class experimental therapy lemborexant in Alzheimer’s patients with Irregular Sleep-Wake Rhythm Disorder (ISWRD).
Read More
- MHRA approves new treatment for severe alopecia areata
- Aplagon doses first patient in phase 2a trial of APAC
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
- UCB reports superiority of bimekizumab in psoriatic arthritis study
- Kainova reports positive results for DT‑9081 in advanced solid tumours
